Plain-English translation of NCT07662655 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 1 — Testing in a small group (usually 20–80 people) to find a safe dose and watch for side effects.
This trial is testing a new procedure called percutaneous pulmonary artery denervation (PADN) — a minimally invasive technique that uses a catheter to block nerves in the lung arteries. The study is for people who developed high blood pressure in their lungs after having a previous heart valve repair. Researchers want to see if this new treatment, combined with standard heart medications, works better than medications alone.
Some patients develop high lung pressure even after their heart valve has been successfully repaired and they are taking all the recommended medications. This trial exists to find out whether blocking the nerves that control lung artery tension can help lower this pressure and improve how patients feel.
You likely qualify if…
You likely don't qualify if…
If you join this study, you will be randomly assigned to either receive the nerve-blocking procedure plus your regular heart medications, or to continue with medications alone. The procedure involves inserting a thin tube (catheter) into your blood vessels to reach the lung arteries, where special energy is used to block nerves. You will have follow-up visits to check how you're doing and measure how well the treatment is working.
AI-generated summary from trial data · Jul 1, 2026 · Not medical advice
China